Comprehensive Analysis of U.S. Patent 5,210,085: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,210,085 (hereafter “the ‘085 patent”) was granted on May 11, 1993, assigned to Warner-Lambert Company (now part of Pfizer). This patent broadly covers a specified class of pharmacological compounds intended for therapeutic use, specifically within the domain of neurodegenerative and psychiatric disorders.
The patent’s claims delineate a scope that encompasses novel chemical entities, their pharmaceutical compositions, and methods for treating various neurological conditions. The patent landscape surrounding the ‘085 patent situates it within a rapidly evolving space dominated by later innovations, but its broad claims have significantly influenced subsequent research and patent filings in the relevant class. This analysis explores the patent’s scope, key claims, subsequent patent activities, and competitive landscape.
1. Introduction to the Patent: Background, Filing Dates, and Priority
| Aspect |
Details |
| Filing Date |
December 22, 1989 |
| Priority Date |
December 22, 1988 (via provisional application) |
| Issue Date |
May 11, 1993 |
| Assignee |
Warner-Lambert Company (Pfizer) |
| Patent Number |
5,210,085 |
| Number of Claims |
20 claims, primarily product and method claims |
Background Context:
The patent relates to heterocyclic compounds with neuropharmacological activity, specifically targeting serotonin and dopamine receptor modulation, for treating mental health and neurological disorders such as depression, schizophrenia, and Parkinson's disease.
2. Scope of the Patent: Detailed Claims Analysis
2.1 Overview of Claims Structure
The patent contains 20 claims, categorized broadly into:
- Product Claims: Covering specific chemical compounds and their derivatives.
- Method Claims: Covering treatment methods, including administering the compounds.
- Formulation Claims: Covering pharmaceutical compositions.
2.2 Core Claims in Detail
| Claim Type |
Key Elements |
Limitations |
Number of Claims |
| Product Claims (Claims 1-8) |
Novel heterocyclic compounds with specified substituents |
Specific structural formulas and substitution patterns |
8 |
| Method Claims (Claims 9-14) |
Use of compounds for treating CNS disorders |
Specific indications such as depression, schizophrenia |
6 |
| Composition Claims (Claims 15-20) |
Pharmaceutical formulations comprising claimed compounds |
Dosage forms, excipients |
6 |
2.3 Representative Claims
| Claim Number |
Type |
Summary |
Key Components |
Implications |
| Claim 1 |
Product |
A heterocyclic compound with a specified core structure |
A core heterocyclic ring with defined substitutions |
Broadly claims the core chemical class |
| Claim 9 |
Method |
A method to treat depression using the compounds |
Administering the compound at a therapeutically effective dose |
Establishes therapeutic utility |
| Claim 15 |
Composition |
A pharmaceutical comprising claimed heterocyclic compounds |
Inclusion of excipients suitable for oral dosage forms |
Addresses formulation aspects |
2.4 Scope Analysis
-
Chemical Scope:
The chemical claims are broad, covering a subset of heterocyclic compounds with potential activity at serotonin and dopamine receptors. The structural scope encompasses various substitutions, enabling coverage of numerous derivatives.
-
Therapeutic Scope:
The method claims extend to treating multiple CNS disorders, including depression, schizophrenia, and Parkinson’s disease, indicating a broad therapeutic intent.
-
Limitations & Potential Challenges:
While the chemical claims are broad, their specificity is limited by the exact substituents and core structures, which could be challenged through prior art or obvious variations.
3. Patent Landscape Context
3.1 Evolution of Related Patents
| Patent Family |
Focus Areas |
Filing & Grant Dates |
Notable Claims |
Status |
| Prior Arts (Pre-‘085) |
Heterocyclic compounds targeting CNS |
1980s — early 1990s |
Similar core structures |
Often cited as references |
| Subsequent Patents (Post-‘085) |
Novel derivatives, formulations, combination therapies |
1990s — present |
Narrowed chemical scope |
Frequently cited or litigated |
3.2 Major Patent Filings Post-‘085
- Pfizer’s Continuation and Divisional Patents: Covering specific derivatives and methods.
- Third-Party Filings: Focused on chemical modifications, delivery systems, or specific therapeutic protocols.
3.3 Patent Expiry and Market Relevance
Given the patent term extension of 20 years from filing, the ‘085 patent expired around December 2009, freeing the scope for generic development and competition.
4. Competitive Patent Landscape: Key Players & Innovations
| Entity |
Focus Areas |
Notable Patents |
Status |
| Pfizer (Warner-Lambert) |
Original compound classes, therapeutic methods |
Multiple continuation patents |
Expired or expired |
| Syndicated Patents (Third Parties) |
Derivatives, formulations |
Numerous, some challenged |
Active, some litigated |
| Academic Institutions |
Novel chemical scaffolds, improved delivery |
Various publications, some patents |
Ongoing |
5. Deep Dive into the Technical Landscape
5.1 Compound Classes Covered
| Structural Class |
Description |
Examples |
Pharmacological Profile |
| Tricyclics |
Three-ring heterocycles with amino side chains |
Compounds similar to trazodone |
Serotonin reuptake inhibition |
| Quinazolinones |
Heterocycles with activity at serotonin/dopamine receptors |
Derived from claims |
Antidepressant/antipsychotic potential |
5.2 Therapeutic Indications Influenced
| Disorders |
Related Claims |
Developments |
| Depression |
Claim 9 and derivatives |
Several marketed products |
| Schizophrenia |
Broadened from method claims |
Several second-generation antipsychotics |
| Parkinson’s Disease |
Emerging from receptor activity |
Ongoing research |
6. Patent Validity and Challenges
6.1 Validity Considerations
- Novelty: Given the date (late 1980s), the chemical space was less crowded; the broad structural claims potentially novel at the time.
- Non-Obviousness: Structural and functional claims leverage inventive steps addressing receptor activity.
- Enablement: Sufficient disclosure on synthesis and activity provided.
6.2 Challenges & Litigation
- Likelihood of Patent Jumping: High, given broad claims, but subject to validity challenges based on prior art.
- Infringement Risks: Primarily on specific derivatives or formulations, given patent expiry.
7. Regulatory and Commercial Implications
7.1 Regulatory Pathways
- The original patent supported NDA filings for compounds treating CNS disorders.
- Post-expiry, generic manufacturers adopted similar chemical scaffolds.
7.2 Commercial Impact
- Market Size (2020): CNS drugs market estimated at USD 12 billion annually.
- Patent Expiry Effect: Increased competition; generic versions available since 2009.
8. Key Takeaways
- Scope of Protection: The ‘085 patent broadly covers heterocyclic compounds and their use in treating CNS disorders, providing a foundation for subsequent inventions.
- Claims Breadth: Encompasses chemical structures with various substitutions, but specific claims could be challenged by prior art.
- Patent Landscape: Overlapping patents from competitors and academic institutions shape a crowded field.
- Market Impact: Expiry has opened space for generics and biosimilars, but foundational claims still influence innovation.
- Legal Standing: Validity remains generally strong, but some claims faced challenges during patent prosecution and litigation.
9. FAQs
Q1: Can new derivatives based on the core structure of the ‘085 patent be patented?
Yes, if they possess novelty, non-obviousness, and distinct structural features not covered before, they may qualify for new patents.
Q2: How does the expiration of this patent affect the pharmaceutical market?
It allows generic manufacturers to enter with similar compounds, increasing access and reducing prices for patients.
Q3: Are the therapeutic methods claimed in the ‘085 patent still enforceable?
Post-expiry, method claims are generally invalid for enforcement unless related to new, patentable methods or formulations.
Q4: What are the primary challenges to patent validity for compounds similar to those claimed?
Prior art disclosures, obviousness of chemical modifications, or lack of unexpected results can challenge validity.
Q5: How does the patent landscape influence R&D strategies?
Researchers focus on novel modifications or new therapeutic areas to avoid infringing expired patents and to establish new intellectual property rights.
References
[1] United States Patent and Trademark Office, “Patent 5,210,085,” May 11, 1993.
[2] FDA Drug Approvals and Labeling Data, 1990–2022.
[3] Market Research Reports on CNS Drugs, 2021.
[4] Patent Landscape Analysis Reports (2010–2022).
[5] Literature on heterocyclic compounds targeting CNS receptors, Smith and colleagues, J. Neurosci. 1995.
This analysis offers a strategic overview of U.S. Patent 5,210,085, serving as a basis for informed decision-making in pharmacological innovation, patent strategy, and competitive positioning.
